How should resistance to androgen deprivation therapy in prostate cancer be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Resistance to Androgen Deprivation Therapy in Prostate Cancer

When prostate cancer progresses to castration-resistant disease (CRPC), continue ADT to maintain castrate testosterone levels (<50 ng/dL) and add sequential therapies based on prior treatment history, biomarker status, and disease characteristics. 1, 2

Initial Assessment at Castration Resistance

When disease progresses on ADT, immediately:

  • Confirm castrate testosterone level (<50 ng/dL or <1.7 nmol/L) 2
  • Perform metastatic lesion biopsy if feasible
  • Test for MSI-H/dMMR status (if not previously done) 1, 2
  • Test for HRR gene alterations (BRCA1/2, ATM, PALB2, FANCA, RAD51D, CHEK2, CDK12) - both germline and tumor 1, 2
  • Obtain PSMA-PET imaging for treatment planning 1, 2
  • Assess tumor mutational burden (TMB) 2

Critical pitfall: Never discontinue ADT when disease becomes castration-resistant. The androgen receptor pathway remains the primary driver even in resistant disease. 2, 3

Treatment Algorithm Based on Prior Therapy

For Patients Previously on ADT Alone (No Prior ARPI or Docetaxel)

First-line options 1:

  • Abiraterone + prednisone (PFS HR 0.66, OS HR 0.74) OR
  • Enzalutamide (PFS HR 0.40, OS HR 0.63)

Special populations:

  • HRR gene alterations (especially BRCA1/2): Combine PARP inhibitor with ARPI for superior survival benefit 1
  • MSI-H or dMMR: Pembrolizumab 1, 2
  • Bone-only symptomatic disease: Radium-223 1, 2
  • Oligometastatic disease: Consider metastasis-directed radiation or surgery after multidisciplinary discussion 1
  • Indolent disease (PSADT >10 months, asymptomatic, low-volume): Sipuleucel-T or continued monitoring 1, 2

For Patients Previously on ADT + Docetaxel (No Prior ARPI)

Preferred options 1:

  • Abiraterone + prednisone (PFS HR 0.66, OS HR 0.74) OR
  • Enzalutamide (PFS HR 0.40, OS HR 0.63)

Alternative: Cabazitaxel (PFS HR 0.74, OS HR 0.70 vs mitoxantrone) 1

For Patients Previously on ADT + ARPI + Docetaxel (Triple Therapy)

This represents the most challenging scenario with inherently resistant disease. Treatment selection depends critically on biomarker status 1:

PSMA-positive disease:

  • 177Lu-PSMA-617 (preferred) - PFS HR 0.40, OS HR 0.62 1

HRR gene alterations (BRCA1/2, ATM, etc.):

  • Olaparib monotherapy - PFS HR 0.49 (though OS benefit not statistically significant: HR 0.79) 1
  • Rucaparib (TRITON-3 data) 1

PSMA-negative, HRR-negative disease:

  • Cabazitaxel (especially if prior ARPI was enzalutamide or abiraterone - CARD trial showed PFS HR 0.54, OS HR 0.64 vs switching ARPIs) 1
  • Radium-223 for bone-only symptomatic disease 1
  • Pembrolizumab if MSI-H/dMMR 1

Heavily pretreated patients:

  • Cabazitaxel + carboplatin (PFS HR 0.69 vs cabazitaxel alone) 1
  • Carboplatin monotherapy
  • Best supportive care with palliative intent 1

Key Sequencing Principles

The CARD trial fundamentally changed treatment sequencing: In patients progressing on an ARPI, cabazitaxel is superior to switching to another ARPI (abiraterone or enzalutamide), with significant PFS and OS benefits. 1 This means cross-resistance between ARPIs is substantial, and chemotherapy should be prioritized over ARPI switching in most cases.

Early biomarker testing is essential: Given significant patient attrition with each line of therapy in real-world practice, identify HRR alterations and PSMA status before starting mCRPC treatment to optimize first-line therapy and avoid missing opportunities for targeted treatments. 1

BRCA1/2 alterations warrant immediate attention: These patients derive the most significant survival benefit from PARP inhibitor combinations, making early genetic testing critical. 1

Mechanisms of Resistance to Consider

While treatment decisions are algorithm-based, understanding resistance mechanisms helps anticipate progression 3, 4, 5:

  • AR amplification and mutations (especially ligand-binding domain mutations)
  • AR splice variants (AR-V7)
  • Increased intratumoral androgen synthesis
  • Activation of alternative pathways (PI3K/AKT, glucocorticoid receptor)
  • Neuroendocrine differentiation
  • DNA repair defects
  • Lineage plasticity

These mechanisms inform emerging therapies including AR degraders (PROTACs), non-ligand binding domain inhibitors, CYP11A1 inhibitors, and bipolar androgen therapy, though most remain investigational. 4, 5, 6

Common Pitfalls to Avoid

  1. Stopping ADT at castration resistance - This accelerates progression 2
  2. Delaying biomarker testing - HRR and PSMA status should be known before selecting mCRPC therapy 1
  3. Sequential ARPI use without intervening chemotherapy - CARD trial shows this is inferior to cabazitaxel 1
  4. Missing MSI-H/dMMR patients - These respond to pembrolizumab regardless of other factors 1, 2
  5. Failing to refer BRCA-positive patients for genetic counseling - Family cascade testing is indicated 2

Supportive Care Throughout

All patients with mCRPC should receive best supportive care addressing ADT-related adverse effects including cardiovascular risk, bone health, metabolic complications, and quality of life concerns. 2, 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.